Erratum: Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi

Guo, Hao; Zhang, J; Inal, Cengiz; Nguyen, Thu Anh; Fruehauf, Johannes; Keates, Andrew C.; Li, C J

doi:10.1038/gt.2011.9

Cited by 3 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delivery of nucleic acids by bacteria, or bactofection, has been previously applied, for example by Agrobacterium for CRISPR/CAS9 gene-editing in wheat (60); L. monocytogenes, E. coli and S. typhimurium for siRNAs, short ORF-containing RNAs for GFP, and plasmids (28,36,(61)(62)(63)(64)(65)(66)(67)(68)(69), albeit with efficiencies that would hinder viral RNA delivery. Leveraging the flexible tools available for genetic engineering in S. typhimurium, we were able to deliver large viral RNAs more efficiently across a broad range of cell types than those previously reported via engineered S. typhimurium strains (64).…”

Section: Discussionmentioning

confidence: 99%

Engineered bacteria launch and control an oncolytic virus

Singer,

Pabón,

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

The ability of bacteria and viruses to selectively replicate in tumors has led to synthetic engineering of new microbial therapies. Here we design a cooperative strategy wherebyS. typhimuriumbacteria transcribe and deliver the Senecavirus A RNA genome inside host cells, launching a potent oncolytic viral infection. Then, we engineer the virus to require a bacterially delivered protease in order to achieve virion maturation, demonstrating bacterial control over the virus. This work extends bacterially delivered therapeutics to viral genomes, and the governing of a viral population through engineered microbial interactions.One-Sentence SummaryBacteria are engineered to act as a synthetic “capsid” delivering Senecavirus A genome and controlling its spread.

show abstract

Section: Discussionmentioning

confidence: 99%

Engineered bacteria launch and control an oncolytic virus

Singer,

Pabón,

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…S. Typhimurium secretion systems have also been used to efficiently deliver therapeutic agents into the cytosol of cells (Xu et al, 2014;Camacho et al, 2016;Clark-Curtiss and Curtiss, 2018). Currently, the most widely used anticancer agent delivery strategies are: (I) Delivery of genetic material for the eukaryotic expression of antitumor agents or the expression of RNA interference (RNAi) (Lee et al, 2005;Yang et al, 2008;Guo et al, 2011;Yoon et al, 2017;Yoon et al, 2018); (II) Delivery of cytotoxic agents to induce apoptosis of tumor cells (Camacho et al, 2016;Yang et al, 2016); (III) Delivery of immunomodulators to enhance the antitumor immune response (Saltzman et al, 1996;Nishikawa et al, 2006;Bereta et al, 2007;Fensterle et al, 2008;Loeffler et al, 2008;Massa et al, 2013;Schmitz-Winnenthal et al, 2015;Park et al, 2016;Augustin et al, 2021); and (IV) Delivery of Prodrug converting enzymes (King et al, 2002;Nemunaitis et al, 2003;Friedlos et al, 2008).…”

Section: S Typhimurium As a Vector To Deliver Anticancer Agentsmentioning

confidence: 99%

“…However, efficient administration has been a critical limitation (Chen et al, 2018b). S. Typhimurium has shown efficient delivery of RNAi from different oncogenes (Yang et al, 2008;Guo et al, 2011;Yoon et al, 2018). S. Typhimurium was modified to deliver short hairpin RNA specifically targeted to the alpha subunit of inhibin (sh-INHA) from a eukaryotic expression plasmid.…”

Section: Delivery Of Genetic Materialsmentioning

confidence: 99%

“…Other strains deficient in amino acids that have shown a good safety profile and antitumor effects are strains deficient in aromatic amino acid biosynthesis, such as the aroA, aroC, and aroD mutants (Grille et al, 2014;Jin et al, 2017;Yoon et al, 2017;Bascuas et al, 2018). In addition, aro mutants are attenuated when inoculated by different routes of administration (Yang et al, 2008;Guo et al, 2011;Bascuas et al, 2018). The attenuation of these mutants is due to their inability to replicate and survive in mammalian cells, which considerably improves their safety profile to the host.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment

Pérez Jorge,

Gontijo,

Brocchi

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Conventional cancer therapies have many limitations. In the last decade, it has been suggested that bacteria-mediated immunotherapy may circumvent the restrictions of traditional treatments. For example, Salmonella enterica is the most promising bacteria for treating cancer due to its intrinsic abilities, such as killing tumor cells, targeting, penetrating, and proliferating into the tumor. S. enterica has been genetically modified to ensure safety and increase its intrinsic antitumor efficacy. This bacterium has been used as a vector for delivering anticancer agents and as a combination therapy with chemotherapy, radiotherapy, or photothermic. Recent studies have reported the antitumor efficacy of outer membrane vesicles (OMVs) derived from S. enterica. OMVs are considered safer than attenuated bacteria and can stimulate the immune system as they comprise most of the immunogens found on the surface of their parent bacteria. Furthermore, OMVs can also be used as nanocarriers for antitumor agents. This review describes the advances in S. enterica as immunotherapy against cancer and the mechanisms by which Salmonella fights cancer. We also highlight the use of OMVs as immunotherapy and nanocarriers of anticancer agents. OMVs derived from S. enterica are innovative and promising strategies requiring further investigation.

show abstract

“…The signaling pathway can be obstructed through two methods: either at the protein level using monoclonal antibody 15 , or at the gene level using RNA interference (RNAi) technology. Patisiran, the world's rst RNAi drug, was approved by the U.S. Food and Drug Administration in 2018 and essentially cured hereditary transthyroxin amyloidosis, or h-ATTR, by silencing the disease-causing gene 16 .…”

Section: Introductionmentioning

confidence: 99%

Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement

Jia

Wei²,

Zhou

et al. 2023

Preprint

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the most prevalent type of aggressive liver cancer, accounts for the majority of liver cancer diagnoses and fatalities. Despite recent advancements in HCC treatment, it remains one of the deadliest cancers. Radiation therapy (RT) is among the locoregional therapy modalities employed to treat unresectable or medically inoperable HCC. However, radio-resistance poses a significant challenge. It has been demonstrated that RT induced the upregulation of programmed death ligand 1 (PD-L1) on tumor cells, which may affect response to PD-1-based immunotherapy, providing a rationale for combining PD-1/PD-L1 inhibitors with radiation. Here, we utilized attenuated Salmonella as a carrier to explore whether attenuated Salmonella carrying siRNA-PD-L1 could effectively enhance the anti-tumor effect of radiotherapy on HCC-bearing mice. Our results showed that a combination of siRNA-PD-L1 and radiotherapy had a synergistic anti-tumor effect by inhibiting the expression of PD-L1 induced by radiation therapy. Mechanistic insights indicated that the combination treatment significantly suppressed tumor cell proliferation, promoted cell apoptosis, and stimulated immune cell infiltration and activation in tumor tissues. Additionally, the combination treatment increased the ratios of CD4+ T, CD8+ T, and NK cells from the spleen in tumor-bearing mice. This study presents a novel therapeutic strategy for HCC treatment, especially for patients with RT resistance.

show abstract

Erratum: Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi

Cited by 3 publications

References 0 publications

Engineered bacteria launch and control an oncolytic virus

Engineered bacteria launch and control an oncolytic virus

Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment

Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement

Contact Info

Product

Resources

About